• Citer

Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.

par Westphal, Manfred;Ylä-Herttuala, Seppo Pasi Antero S.;Martin, John;Warnke, Peter;Menei, Philippe P;Eckland, David D;Kinley, Judith J;Kay, Richard;Ram, Zvi;De Witte, Olivier
Référence Lancet oncology, 14, 9, page (823-833)
Publication Publié, 2013-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.
Auteur:	Westphal, Manfred; Ylä-Herttuala, Seppo Pasi Antero S.; Martin, John; Warnke, Peter; Menei, Philippe P; Eckland, David D; Kinley, Judith J; Kay, Richard; Ram, Zvi; De Witte, Olivier
Informations sur la publication:	Lancet oncology, 14, 9, page (823-833)
Statut de publication:	Publié, 2013-08
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adenoviridae -- genetics
	Adolescent
	Adult
	Aged
	Antiviral Agents -- therapeutic use
	Brain Neoplasms -- genetics -- mortality -- pathology -- therapy
	Combined Modality Therapy
	Female
	Follow-Up Studies
	Ganciclovir -- therapeutic use
	Genetic Therapy
	Glioma -- genetics -- mortality -- pathology -- therapy
	Humans
	Male
	Middle Aged
	Neoplasm Grading
	Prognosis
	Survival Rate
	Thymidine Kinase -- therapeutic use
	Young Adult
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(13)70274-2
	info:pii/S1470-2045(13)70274-2
	info:pmid/23850491